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Background:  Obinutuzumab  combined  with  chlorambucil  (GClb)  has  shown  to  be superior  to  rituximab
combined  with  chlorambucil  (RClb)  and  chlorambucil  (Clb)  in newly  diagnosed  patients  with  chronic
lymphocytic  leukaemia  (CLL).  This  study  evaluates  the  cost-effectiveness  per  life-year  and  quality-
adjusted  life-year  (QALY)  of GClb  compared  to RClb,  Clb, and  ofatumumab  plus  chlorambucil  (OClb)
in  The  Netherlands.
Methods:  A  Markov  model  was developed  to assess  the  cost-effectiveness  of  GClb, RClb,  Clb  and  other
treatments  in  the United  Kingdom.  A  country  adaptation  was made  to estimate  the  cost-effectiveness
of these  therapies  in  The  Netherlands  using  Dutch  unit  costs  and  Dutch  data  sources  for  background
mortality  and  post-progression  survival.
Results:  An  incremental  gain  of  1.06  and  0.64  QALYs  was  estimated  for GClb  compared  to  Clb  and  RClb
respectively,  at additional  costs  of D 23,208  and  D 7254  per  patient.  Corresponding  incremental  cost-ost-effectiveness
osts
effectiveness  ratios  (ICERs)  were  D  21,823  and  D 11,344  per  QALY.  Indirect  treatment  comparisons  showed
an  incremental  gain  varying  from  0.44  to  0.77  QALYs  for  GClb  compared  to OClb  and  additional  costs
varying  from  D 7041  to D 5028  per  patient.  The  ICER  varied  from  D 6556  to  D  16,180 per  QALY.  Sensitivity
analyses  showed  the robustness  of  the  results.
Conclusion:  GClb  appeared  to  be a cost-effective  treatment  strategy  compared  to  RClb,  OClb  and  Clb.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd.  This  is an open  access  article  under  the CC  BY  license. Introduction
Chronic lymphocytic leukaemia (CLL) is the most common type
f leukaemia occurring in the Western world [1]. The age stan-
ardised incidence rate in the Netherlands is 3.8 per 100,000
2]. Five-year relative overall survival (OS) increased from 61% in
989–1993 to 70% in 2004–2008 for males, and for females from
1% to 76%. The majority of the patients diagnosed with CLL are
bove 65 years and have comorbidities.
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-
djusted life-year; ITC, indirect treatment comparison.
∗ Corresponding author. P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
E-mail address: blommestein@bmg.eur.nl (H.M. Blommestein).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.leukres.2016.09.005
145-2126/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article(http://creativecommons.org/licenses/by/4.0/).
A wait and see approach is common for Dutch patients diag-
nosed with CLL [3]. However, eventually many patients receive
treatment. Currently, in the Netherlands, ﬂudarabine, cyclophos-
phamide and rituximab is the recommended regimen for ﬁt
patients, i.e. patients without comorbidities, usually younger than
65–70 years. Chlorambucil plus a monoclonal antibody is recom-
mended for less ﬁt patients, i.e. patients with some comorbidities
and/or WHO  performance status 0–2. For unﬁt patients, i.e patients
with several comorbidities and/or WHO  performance status 3–4,
chlorambucil or chlorambucil plus a monoclonal antibody is rec-
ommended [4]. There are several monoclonal antibodies available
for newly diagnosed patients with CLL such as rituximab, obin-
utuzumab and ofatumumab. The efﬁcacy of these therapies was
investigated in randomised phase III studies, i.e. the CLL11 [5] and
COMPLEMENT 1 [6]. The CLL11 study was a three arm phase III
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tudy that compared both obinutuzumab combined with chloram-
ucil (GClb) and rituximab combined with chlorambucil (RClb)
o chlorambucil (Clb) in newly diagnosed patients with CLL who
equired treatment. Median PFS was 26.7, 16.3 and 11.1 months
or GClb, RClb and Clb, respectively [5]. The COMPLEMENT 1 study
ompared ofatumumab combined with chlorambucil (OClb) to Clb,
nd showed a median PFS of 22.4 and 13.1 months, respectively
6]. While a direct comparison between GClb and OClb is not avail-
ble, it is possible to perform an indirect comparison since both
he CLL11 and COMPLEMENT 1 trial included Clb as comparative
reatment.
A comprehensive cost study among patients with CLL in the
etherlands showed that costs varied considerably between treat-
ents, with Clb having the lowest total monthly costs [7]. The
ost-effectiveness of GClb compared to RClb, OClb and Clb in the
nited Kingdom (UK) was calculated by Becker et al. [8]. How-
ver, these results might not be applicable to the Dutch context.
irst, input parameters such as drug prices and costs related to
upportive care may  not be similar. Second, guidelines for con-
ucting economic evaluations in the Netherlands are different from
he guidelines in the UK. For example, discount rates for effects
nd costs are different [9,10]. Therefore, we aim to evaluate the
ost-effectiveness of GClb compared to RClb, OClb and Clb in The
etherlands using an adjusted version of the UK model [8].
. Materials and methods
Evaluating the cost-effectiveness of treatments often requires
odelling to bring together data sources and to extrapolate costs
nd effects over time. Modelling enables to compare all treatment
ptions, not only the options that have been compared in a clinical
tudy [11]. Modelling consists of several steps including creating a
odel structure (consisting of health states), assigning transition
robabilities to each health state and selecting input parameters
uch as utility values and costs for each health state. Finally, sensi-
ivity analyses are performed to examine the impact of assumptions
nd uncertainty across input parameters.
.1. Model structure
A Markov model enables the study of the course of the disease
y simplifying the disease course in health states. A Markov model
ncluding three mutually exclusive health states, i.e Progression
ree Survival (PFS) (with/without therapy), Progression (Refrac-
ory/Relapsed lines) and Death (Fig. 1) was developed by Becker
t al. to assess the cost-effectiveness of GClb, RClb, Clb and other
reatment options in the UK [8]. A country adaptation to the UK
odel was made to estimate the cost-effectiveness of these thera-
ies in The Netherlands from a healthcare perspective (Table 1).
.2. Transition probabilities
Transition probabilities determine how patients move between
ealth states in the Markov model. Transition probabilities from
he PFS health state were derived from the CLL11 study. Observed
aplan-Meier data was extrapolated using several parametric
istributions (i.e. Exponential, Weibull, Log-logistic, Lognormal,
amma  and Gompertz). The goodness of ﬁt of the distributions to
he data was assessed using the Akaike Information Criterion (AIC),
raphical assessment and knowledge of the expected extrapolation
f PFS [8].
To compare GClb with OClb, an indirect treatment comparisonITC) was made using a ﬁxed-effects network meta-analysis (NMA).
esides the CLL11, the COMPLEMENT 1 trial was included in this
etwork. Table 2 provides an overview of the patient characteris-
ics of the patients in CLL11 and COMPLEMENT 1. In the study by Research 50 (2016) 37–45
Becker et al. the natural logarithms of the estimated hazard ratios
were used to inform the ITC (unpublished results). In the current
study, two  scenarios for the ITC were created. Besides the natural
logarithms of the estimated hazard ratios (Scenario A), the observed
median PFS was used to inform the ITC (Scenario B). The latter anal-
yses were performed with an adapted version of the WinBUGS code
of Dias et al. [12,13]. Transition probabilities were supplemented
with Dutch background mortality [14].
Transitions probabilities from the Progression (Refrac-
tory/Relapsed lines) health state were obtained from the Dutch
Population based HAematological Registry for Observational Stud-
ies (PHAROS-registry) [15,16]. A population similar to the CLL11
population was selected from this registry by selecting patients
with CLL (i.e. morphology code 9670 and 9823) who  received
ﬁrst-line treatment with either Clb (N = 398) or RClb (N = 43). Since
date of progression was  frequently unavailable for patients in the
PHAROS-registry, the start of second-line treatment was  used as a
proxy for all patients. Patients who  did not receive a subsequent
therapy after ﬁrst-line therapy were excluded (N = 119), just as
patients who  have died during ﬁrst-line therapy (N = 92). Table 2
provides an overview of the patient characteristics of the CLL11
study and the PHAROS-registry. To estimate the probability of
transitioning from Progression to Death, a range of parametric
survival distributions were compared. The distributions were
assessed for their goodness of ﬁt to the data using the AIC and
Bayesian Information Criterion (BIC). Additionally, the parametric
functions were assessed graphically. Finally, the impact of ﬁrst-line
treatment and prognostic factors (i.e. age, sex, Binet stage, WHO
performance status and the number of comorbidities) on post
progression survival (PPS) was  tested. OS was signiﬁcantly inﬂu-
enced by age and comorbidities. Prevalence of ≥2 comorbidities
and/or age ≥65 years of the COMPLEMENT 1 (83%) was comparable
to the PHAROS population (82%). However, the average number
of comorbidities based on the cumulative illness rating scale in
the CLL11 study was  much higher. First-line treatment did not
signiﬁcantly inﬂuence OS, however, this could be related to the
fact that only 10 of the 230 patients had received RClb as ﬁrst-line
treatment.
The PHAROS-registry has been approved by the Medical Ethics
Committee of the Erasmus Medical Center Rotterdam (MEC-2011-
200), The Netherlands (metc@erasmusmc.nl) that serviced as the
Dutch Medical Ethics committee. The ethic committee decided that
informed consent was not to be sought, as is the policy for the
Netherlands Cancer Registration.
2.3. Health state utilities
Utility values generally range between 0 (death) and 1 (perfect
health). The time a patient spent in each health state was  weighted
using the utilities provided by Kosmas et al. [17]. The values are pre-
sented in Table 1 and are in line with the cost-effectiveness model
published by Becker et al. [8].
2.4. Drug costs and drug administration costs
In the base case, drug costs were based on the planned dose
based on average patient characteristics. Average weight and Body
Surface Area were derived from the PHAROS-registry. The costs for
entire vials were applied assuming no vial sharing. Obinutuzumab
and ofatumumab are given in a ﬁxed dose, and therefore do not
depend on patient characteristics [5,6]. Dutch drug costs were
derived from reference price lists (i.e. Z-index).The administration costs of obinutuzumab, rituximab or ofatu-
mumab  infusion were assumed to be equal to the costs of a day
care treatment, and to be in accordance with the number of cycles
[5,6].
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Table 1
Model input parameters of the UK model and the Dutch country adaptation.
Input parameters UK model Sources Country adaptation Sources
Transition probabilities
From the PFS health state CLL11 (and ITC) Goede et al. [5] CLL11 (and ITC) Goede et al. [5]
From the Progression health state CLL5 (CLL8 in sensitivity
analyses)
Eichhorst et al. [19], Hallek et al. [22] PHAROS-registry (CLL5 in
sensitivity analyses)
Huijgens et al. [15]
Utilities
PFS health state, under oral Treatment 0.71 Kosmas et al. [17] 0.71 Kosmas et al. [17]
PFS health state, under iv Treatment 0.67 Kosmas et al. [17] 0.67 Kosmas et al. [17]
PFS health state on initial therapy with
increased hospital visits
0.55 Kosmas et al. [17] 0.55 Kosmas et al. [17]
PFS health state, after Treatment 0.82 Kosmas et al. [17] 0.82 Kosmas et al. [17]
Progression health state 0.60 Kosmas et al. [17] 0.60 Kosmas et al. [17]
Cost data
Drugs
Obinutuzumab (1000 mg)  £2,803.00 British National Formulary, October 2013 D 4,139.43 Dutch reference price lists (Z-index)
Rituximab (500 mg)  £873.15 British National Formulary, October 2013 D 1,378.40 Dutch reference price lists (Z-index)
Chlorambucil (per tablet) £1.62 British National Formulary, October 2013 D 1.18 Dutch reference price lists (Z-index)
Ofatumumab (1000 mg)  £1,820.00 British National Formulary, October 2013 D 2,448.60 Dutch reference price lists (Z-index)
Weekly  Supportive care costs
PFS health state £8.13 2012–2013 DH HRG (WF01A) D 70.51 Holtzer-Goor et al. [7]
Progression health state £24.38 2012–2013 DH HRG (WF01A) D 418.44 Holtzer-Goor et al. [7]
Treatment administration
Administration cost per treatment cycle £343.00 2012-13 DH HRG (SB15Z) D 184.00 Gaultney et al. [23]
Adverse events
Anaemia £2088 2012-13 DH HRG tariffs (SA03F) D 1822 Bouwmans et al. [18]
Febrile neutropenia £3894 2012-13 DH HRG tariffs (PA45Z) D 2853 Bouwmans et al. [18]
Infection £773 Unknown D 2429 Opendisdata 2013 19999004
Infusion related reaction: bronchospasm £359 2012-13 DH HRG tariffs (WA16Y) D 995 Opendisdata 2013 109699017/109699018
Infusion related reaction: chills £359 2012-13 DH HRG tariffs (WA16Y) D 758 Opendisdata 2013 182199008
Infusion related reaction: dyspnoea £359 2012-13 DH HRG tariffs (WA16Y) D 995 Opendisdata 2013 109699017/109699018
Infusion related reaction: hypertension £359 2012-13 DH HRG tariffs (WA16Y) D 616 Opendisdata 2013 90301004
Infusion related reaction: hypotension £359 2012-13 DH HRG tariffs (WA16Y) D 616 Opendisdata 2013 90301004
Infusion related reaction: pyrexia £359 2012-13 DH HRG tariffs (WA16Y) D 758 Opendisdata 2013 182199008
Infusion related reaction: vomiting £359 2012-13 DH HRG tariffs (WA16Y) D 758 Opendisdata 2013 182199008
Leukopenia £942 2012-13 DH HRG tariffs (PA48B) D 1788 Opendisdata 2013 182199003
Lymphopenia £942 2012-13 DH HRG tariffs (PA45Z) D 1788 Opendisdata 2013 182199003
Neutropenia £3894 2012-13 DH HRG tariffs (PA45Z) D 1299 Opendisdata 2013 182199003
Pneumonia £1353 2012-13 DH HRG tariffs (DZ11C) D 1593 Opendisdata 2013 109999003/109999064
Rash  maculo-papular £500 2012-13 DH HRG tariffs (PA66Z) D 758 Opendisdata 2013 182199008
Thrombocytopenia £1847 2012-13 DH HRG tariffs (SA12F) D 3424 Bouwmans et al. [18]
Background mortality Data representing the
2008–2012 UK population –
Total population
Data representing the 2013 NL population Statistics Netherlands [14]
Discount rates for outcome and costs 3.5% and 3.5% 4.0% and 1.5%
Abbreviations: DH HRGs, Department of Health Healthcare Resource Groups.
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Fig. 1. Markov model structure (obtained from Becker et al. [8]).
The model includes three mutually exclusive health states: ‘progression-free survival (PFS) (with/without therapy)’, ‘progression (refractory/relapsed lines)’ and ‘death’. All
patients start off in the initial treatment health state and can move to another health state or stay in the same state at the end of each subsequent analysis cycle. The possible
transitions are indicated by the arrows [5].
Table 2
Patient and disease characteristics of the CLL11, Complement1 and PHAROS registry.
CLL11 CLL11 CLL11 COMPLEMENT 1 COMPLEMENT 1 PHAROS registry
GClb RClb Clb OClb Clb RCLB or CLB
Characteristics 333 330 118 221 226 230
Age,  yr., median (range) 74 (39–89) 73 (40–90) 72 (43–87) 70 (36–91) 69 (35–92) 70 (39–95)
Sex  male, n (%) 203 (61%) 204 (62%) 75 (64%) 142 (64%) 140 (62%) 145 (63%)
ECOG/WHO PS, median 1 1 1
0,1  n(%) 205 (91%) 204 (92%) 150 (97%)
2  n(%) 19 (8%) 17 (8%) 3 (2%)
3–5  n(%) 0 0 1 (1%)
Unknown, n 76
Binet  stage, n(%)
A 74 (22%) 72 (22%) 24 (20%) 70 (31%) 77 (35%) 101 (44%)
B  142 (43%) 135 (41%) 50 (42%) 87 (38%) 74 (33%) 53 (23%)
C  117 (35%) 121 (37%) 44 (37%) 69 (31%) 70 (32%) 76 (33%)
Unmutaed IGHV, % 62% 61% 58% 57% 56% N/A
FISH  cytogenetics not tested/unknown in
79% of the patients
17p-,  n (%) 22 (7%) 20 (7%) 10 (10%) 10 (5%) 17 (8%)
11q-, n (%) 47 (16%) 50 (17%) 14 (14%) 40 (19%) 24 (11%)
12+, n (%) 46 (16%) 47 (16%) 16 (16%) 35 (17%) 34 (16%)
13q-, n (%) 85 (29%) 46 (16%) 32 (33%) 122 (58%) 105 (49%)
Other, n (%) 21 (7%) 85 (29%) 10 (10%)
Normal, n (%) 74 (25%) 21 (7%) 15 (15%) 41 (26%) 64 (37%)
6q-,  n (%) 2 (<1%) 4 (2%)
2-microglobulin, n(%)
<3.5 mg/l 208 (64%) 195 (61%) 70 (61%) 48 (22%) 61 (29%) N/A
≥3.5  mg/l 115 (36%) 127 (39%) 45 (39%) 169 (78%) 153 (71%) N/A
Total  CIRS score, median (range) 8 (0–22) 8 (0–18) 8 (0–18) 8 (4–19) 9 (4–21) N/A
A  Orga
C
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bbbreviations: ECOG, Eastern Cooperative Oncology Group; WHO, World Health
umulative Illness Rating Scale.
The occurrence of adverse events was obtained from the CLL11
nd COMPLEMENT 1 trials. According to the CLL11 study, adverse
vents (grade ≥3) occurred more frequently among patients treated
ith GClb (70%) and RClb (55%) compared to Clb (50%) [5]. The
OMPLEMENT 1 trial revealed that 50% of the patients treated
ith OClb and 43% of the patients treated with Clb experienced
n adverse event (grade ≥3) [5,6]. Unit costs for anaemia (grade
), febrile neutropenia (grade 3 and 4), neutropenia (grade 3 and
) and thrombocytopenia (grade 3 and 4) were derived from the
utch cost study by Bouwmans et al. [18]. The remaining unit costs
or adverse events were obtained from a public database including
ata on average prices paid for health care products provided in
utch hospitals (www.opendisdata.nl). Since health care products
ere not available for adverse events directly, the most appropriate
ealth care product was identiﬁed based on expert opinion..5. Supportive care costs
Costs of supportive care during PFS were derived from a study
y Holtzer-Goor et al. [7]. In this study on real-world costs of CLL innisation; PS, performance status; FISH: Fluorescence in situ hybridization; CIRS,
The Netherlands, total monthly costs per treatment group are pre-
sented. Costs of chemo(immuno-) therapy and hospitalisations due
to other reasons were excluded in order to prevent double counting
in the model. We  assumed that the total monthly costs of patients
treated with Clb (N = 96) best represent the total monthly costs of
patients treated with either GClb, RClb, OClb and Clb only.
Costs of supportive care during PD were also derived from the
study by Holtzer-Goor et al. [7]. However, since this study included
patients diagnosed between 1999 and 2003, treatment prescription
might have changed. Therefore, the PHAROS-registry was used to
provide more recent information on treatment prescription; costs
derived from Holtzer-Goor were weighted using the distribution of
treatments prescribed in second and subsequent lines as observed
in the PHAROS-registry (Appendix A).
2.6. Sensitivity analysesDeterministic sensitivity analyses were conducted to examine
the impact of alternative input parameters on the incremental cost-
effectiveness ratio (ICER). The amount of drugs (without or with
H.M. Blommestein et al. / Leukemia Research 50 (2016) 37–45 41
Table  3
Base-case: Mean costs and effects of GClb, RClb and Clb.
Effects Mean Incremental
GClb RClb Clba GClb vs. Clb RClb vs. Clb GClb vs. RClb
Years in PFS 2.75 1.58 0.99 1.76 0.59 1.17
Years in PD 3.70 4.23 4.29 −0.59 −0.06 −0.53
Total  LYs 6.45 5.81 5.28 1.17 0.53 0.64
QALYs in PFS 2.19 1.23 0.78 1.41 0.46 0.96
QALYs in PD 2.20 2.52 2.55 −0.35 −0.03 −0.32
Total  QALYs 4.39 3.75 3.33 1.06 0.42 0.64
Costs
Total  PFS costs 41,503 22,350 4377 37,125 17,973 19,152
Obinutuzumab 28,608 0 0 28,608 0 28,608
Rituximab 0 14,571 0 0 14,571 −14,571
Chlorambucil 195 230 209 −14 21 −35
Ofatumumab 0 0 0 0 0 0
Drug  administration 1455 1027 0 1455 1027 427
Supportive care PFS 9781 5737 3634 6147 2103 4044
Adverse events 1464 784 534 930 250 680
Total  PD costs 69,467 81,366 83,384 −13,918 −2019 −11,899
Total  costs 110,969 103,716 87,762 23,208 15,954 7254
Costs per LY 19,810 29,967 11,350
Costs per QALY 21,823 37,624 11,344
a Treatment with Clb was only included in the randomisation during the ﬁrst stage of the CLL11.
Table 4
Indirect treatment comparison – Mean costs and effects of GClb and OClb.
Scenario A Scenario B
Effects Mean Incremental Mean Incremental
GClb OClb GClb vs. OClb GClb OClb GClb vs. OClb
Years in PFS 2.75 1.40 1.35 2.75 1.91 0.84
Years in PD 3.70 4.28 −0.58 3.70 4.13 −0.43
Total  LYs 6.45 5.68 0.77 6.45 6.05 0.41
QALYs in PFS 2.19 1.08 1.11 2.19 1.50 0.69
QALYs in PD 2.20 2.55 −0.35 2.20 2.46 −0.26
Total  QALYs 4.39 3.62 0.77 4.39 3.96 0.44
Costs
Total  PFS costs 41,503 23,324 18,178 41,503 25,136 16,367
Obinutuzumab 28,608 0 28,608 28,608 0 28,608
Rituximab 0 0 0 0 0 0
Chlorambucil 195 530 −335 195 530 −335
Ofatumumab 0 16,063 −16,063 0 16,063 −16,063
Drug  administration 1455 1276 179 1455 1276 179
Supportive care PFS 9781 5093 4688 9781 6904 2877
Adverse events 1464 363 1102 1464 363 1102
Total  PD costs 69,467 82,617 −13,150 69,467 78,792 −9326
Total  costs 110,969 105,941 5028 110,969 103,928 7041
6532
6556
v
(
(
r
C
t
a
p
p
1
p
f
b
cCosts per LY 
Costs per QALY 
ial sharing and actual dose or planned dose), treatment duration
actual or according to label) and post progression mortality rate
age adjusted pooled post progression death rate from the PHAROS-
egistry or age adjusted pooled post progression death rate from
LL5 trial [19] as used by Becker et al. [8]) were varied.
Probabilistic sensitivity analysis (PSA) was performed to explore
he joint uncertainty across all input parameters. In the PSA, prob-
bility distributions for input parameters were used instead of
oint estimates to reﬂect the uncertainty of these parameters. Input
arameters were varied simultaneously and the model was run
0,000 times. The following input parameters were varied in the
robabilistic sensitivity analysis (PSA); utilities, the HR derived
rom the ITC, parameters for the parametric PFS and PPS function,
oth the occurrence and costs of adverse events, weekly supportive
are costs and administration costs. 17,364
 16,180
3. Results
Model results showed that GClb was  the most effective treat-
ment strategy, life-years (LYs) were 6.45 while QALYs were 4.39
(Table 3). Treatment with RClb resulted in 5.81 LYs and 3.75 QALYs.
LYs and QALYs for Clb were 5.28 and 3.33, respectively. An incre-
mental gain of 1.17 and 0.64 LYs was estimated for GClb compared
to Clb and RClb respectively, at an additional cost of D 23,208 and
D 7254 per patient. The resulting ICERs were D 19,810 and D 11,350
per LY, respectively. An incremental gain of 1.06 and 0.64 QALYs
was estimated for GCLb compared to Clb and RClb respectively.
The corresponding ICERs were D 21,823 and D 11,344 per QALY.
The ITC for GCLb compared to OClb showed an incremental gain
of 0.77 LYs and 0.77 QALYs for scenario A (Table 4). Additional costs
were D 5028 resulting in an ICER of D 6532 per LY and D 6556 per
QALY. For Scenario B, the ITC for GCLb compared to OClb showed
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Table  5
Results of the deterministic sensitivity analyses.
Costs per QALY
GClb
vs. Clb
RClb vs.
Clb
GClb vs.
RClb
GClb vs. OClb
(scenario A)
GClb vs. OClb
(scenario B)
Base case 21,823 37,624 11,344 6556 16,180
Sensitivity
Utilities
PFS  health state, under oral
treatment (±10%)
0.64 21,314 35,500 11,344 6556 16,180
0.78  22,356 40,018 11,344 6556 16,180
PFS  health state, under iv
treatment (±10%)
0.60 22,271 40,352 11,217 6460 15,766
0.74  21,391 35,241 11,474 6655 16,617
Progression free survival on initial therapy
with fjjjincreased hospital visits (±10%)
0.50 21,909 37,624 11,419 6592 16,338
0.61  21,737 37,624 11,270 6520 16,026
PFS  health state, after treatment
(±10%)
0.74 25,161 41,802 13,415 7755 19,639
0.90  19,266 34,205 9827 5678 13,757
Progression health state (±10%) 0.54 21,127 37,335 10,808 6273 15,272
0.66  22,565 37,917 11,936 6866 17,203
Drug  costs
Vial sharing With vial sharing 21,823 34,842 13,188 6556 16,180
Amount of drug Planned dose 21,838 37,641 11,358 6579 16,220
Amount of drug Planned individual
dose
21,839 37,093 11,723 6596 16,250
Treatment duration According to labela 25,932 39,088 17,046 −2403 −4221
Supportive care costs
Progression-free state (±25%) D 53 20,378 36,384 9763 5028 14,527
D  88 23,267 38,864 12,925 8084 17,833
Progression state (±25%) D 314 25,094 38,814 15,996 10,843 21,537
D  523 18,551 36,434 6692 2270 10,823
Post  progression mortality rate Age adjusted pooled
post progression death
22,659 37,445 13,366 8934 18,131
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a For ofatumumab, only limited information was available on “treatment duration
n  the PFS health state).
n incremental gain of 0.41 LYs and 0.44 QALYs. Incremental costs
ere D 7041 and the ICER was D 17,364 and D 16,180 per LY and
ALY, respectively.
In all comparisons, the main cost drivers for the incremen-
al costs are the drug costs of either obinutuzumab, rituximab or
fatumumab, and the costs of supportive care during progressive
isease.
The results of the deterministic sensitivity analyses are pre-
ented in Table 5. The ICERs, speciﬁcally those derived from the
TC, are sensitive to the utility assigned to the PFS health state
after treatment), treatment duration, i.e. whether the actual treat-
ent duration or the treatment duration according to the label
as implemented in the model, supportive care costs and post-
rogression mortality rate. ICERs are slightly inﬂuenced by the
mount of drugs, i.e. without or with vial sharing and actual dose
r planned dose. Also the post progression mortality rate had little
nﬂuence on the ICERs.
The uncertainty around the total costs and QALYs as obtained
rom the probabilistic sensitivity analysis is shown by Fig. 2A and
. Fig. 2A shows the comparison of GClb vs. Clb, RClb vs. Clb and GClb
s. RClb. This ﬁgure shows that GClb and RClb are more effective
han Clb in 100% of the simulations. Compared to RClb, GClb is also
ore effective in 100% of the simulations.
Fig. 2B shows the results from the PSA for GClb compared to
Clb for scenario A and scenario B. GClb is more effective in 100% of
he simulations in both scenario A and scenario B, and more costly
n 65% and 71% of the simulations for scenario A and scenario B,
espectively.. Discussion
This study evaluated the cost-effectiveness of GClb compared to
Clb, OClb and Clb in The Netherlands. While ICERs for the UK wereding to label”. This deterministic sensitivity analysis assumes 12 cycles (for patients
available, this study managed to calculate ICERs that are applicable
to the Dutch health care setting by using Dutch input parame-
ters. Furthermore, the RCT data was supplemented with real-world
post-progression data to improve the generalisability of the results.
While there is no ofﬁcial threshold in the Netherlands, the National
Health Care Institute has deﬁned categories of maximum addi-
tional costs per QALY depending on disease burden [20]. GClb is
a cost-effective treatment option in the Netherlands for previously
untreated patients with CLL and coexisting conditions given that
the ICERs are below D 50,000 per QALY (i.e. the willingness to pay for
the category with a disease burden between 0.41 and 0.7 [21]). The
ICER of GClb vs Clb was D 19,810 per LY and D 21,823 per QALY, and
the ICER of GClb vs RClb was D 11,350 per LY and D 11,344 per QALY.
In addition, the ITC showed that the ICER of GClb was favourable
compared to OClb; the ICER ranged from D 6532 to D 17,364 per LY
and D 6556 to D 16,180 per QALY. The sensitivity analyses showed
the robustness of the results.
Since a direct comparison between GClb and OClb was not avail-
able, an indirect comparison was performed. This ITC has some
limitations; ﬁrst, only two trials were included and therefore it was
not possible to account for heterogeneity between trials. Second,
assumptions underlying the ITC were violated; the ITC assumes
that the survival curves for the common comparator (i.e. CLB) are
comparable. Although the inclusion criteria of the CLL11 and COM-
PLEMENT 1 study were rather similar, patients in the COMPLEMENT
1 were slightly younger and had more often a Binet stage A. In
addition, the dosing of Clb was different in the two  trials. As a con-
sequence, the median PFS of patients treated with Clb differed, i.e.
11.1 months in the CLL11 and 13.1 months in the COMPLEMENT
1 study. Potentially, the incremental effect of the intervention (i.e.
GClb) could be larger if the comparative treatment is less effec-
tive. Furthermore, the ITC assumes that the proportional hazard
assumption is not violated, while it seemed that the proportional
H.M. Blommestein et al. / Leukemia Research 50 (2016) 37–45 43
A)
B)
F
(
(
h
t
u
n
a
O
f
R
i
c
q
gig. 2. Results of the probabilistic sensitivity analyses.
A)  GClb and RClb compared to Clb, and GClb compared to RClb.
B)  GClb compared to OClb for Scenario A and Scenario B.
azard assumption does not hold over the full period. To overcome
hese limitations, a second scenario (Scenario B) was implemented
sing the median PFS to inform the ITC. Although this method does
ot overcome all limitations, we were able to provide a minimum
nd maximum ICER. Nevertheless, the ICER of GClb compared to
Clb should be interpreted with caution and remains subject for
urther research.
PFS for all treatments was obtained from RCT data. Although
CTs are the golden standard for establishing efﬁcacy, effectiveness
n daily practice is inﬂuenced by many factors including patient
haracteristics and the context of health care delivery. Therefore,
uestions may  arise to what extent the efﬁcacy from the trial is
eneralisible to patients treated in daily practice. Although this issubject for further research, the generalisability regarding coex-
isting conditions was ensured since the CLL11 and COMPLEMENT
1 trial focused on this patient population. Furthermore, post pro-
gression survival (PPS) was obtained from real-world data, i.e. the
PHAROS-registry. Ideally, PPS from the PHAROS-registry would
have been calculated from the date of progression to match the
model structure. However, the date of progression could not be
retrieved from the registry and the start of second-line treatment
was used instead. As a consequence, post progression survival
was based on patients receiving second-line treatment and does
not include untreated patients who  progressed after ﬁrst-line
treatment. While using start of second-line treatment instead of
progression probably underestimates PPS, excluding patients who
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ave died before a second-line could have started may  overestimate
PS.
Supportive care costs were derived from a Dutch study by
oltzer-Goor et al. [7], and were easily applicable to the health
tates in the Markov model. Inclusion criteria for the study by
oltzer-Goor et al. and the CLL11 trial were a little different.
ll patients with CLL (except those suffering from another active
alignant disease or another serious previous malignancy) were
ncluded in the study by Holtzer-Goor et al., whereas the CLL11 trial
as conducted in patients with coexisting conditions. Patients in
he study by Holtzer-Goor et al. were younger, and more often had
 Binet stage A compared to the patients in the CLL11 study. There-
ore, supportive care costs (both during PFS and PD) might have
een underestimated. While this inﬂuences all treatment strate-
ies, the potential underestimation of supportive care costs during
FS is more pronounced in treatment strategies with longer PFS
e.g. GClb) while the underestimation of supportive care costs dur-
ng PD is more pronounced in treatment strategies with longer PD
e.g. Clb). Furthermore, total costs during PD might have been over-
stimated due to extrapolation of weekly supportive care costs in
he model. Weekly costs were derived from the study by Holtzer-
oor based on a mean follow-up period of 6.4 years. However, in
he model the weekly costs were applied until death. Finally, the
istribution of treatments in the cost study of Holtzer-Goor et al.
as adjusted to recently observed treatment patterns to calculate
he costs of supportive care during PD; this assumes that the costs
er treatment strategy will not change over the years and will still
e representative.
Direct costs outside the health care system (including e.g. trav-
lling expenses) were not taken into account just as indirect costs
utside the health care system, such as costs associated to work
ays lost. Including travelling expenses was expected not to inﬂu-
nce results since the costs associated to travelling to the hospital
re very small compared to other costs such as drug costs or sup-
ortive care costs. Since the median age of the population in the
LL11 study was 73 years, we expected productivity costs also to
e negligible.
Preferably, utility values should have been obtained from Dutch
atients with CLL using the EQ-5D. However, since these are
navailable, utility values were obtained from a vignette study by
osmas et al. [17]. One of the disadvantages of vignette studies is
hat people have their own interpretation of the health descrip-
ions. For example, the health state further progression was valued
ith a higher utility value than PFS on second line therapy. Never-
heless, the limitations of the vignette study inﬂuence all treatment
trategies.
Several differences exist between the base case results of the
urrent study and the study by Becker et al. [8]. Total LYs and
ALYs are higher in the current study. For example, LYs for GClb
ere 6.45 in the current study while LYs for GClb were 5.64 accord-
ng to Becker et al. First, PFS is slightly higher in the current study
ue to a different discount rate for effects in the UK (3.5%) and
he Netherlands (1.5%). Second, LYs in PD are substantially higher
n the current study because post-progression was obtained from
he PHAROS-registry. Nevertheless, post-progression was included
n the deterministic sensitivity analyses (based on the CLL5 study
s used by Becker et al. This revealed that although total LYs are
nﬂuenced by this assumption, the impact on the ICER is small. In
ddition to differences for effects, total costs were much higher in
he current study. For example, total costs for GClb were £34,375
D 47,916) according to Becker et al., while total costs for GClb in the
urrent study were D 110,969. This difference is caused by differ-
nces in monthly post-progression costs. In the current study, these
osts were obtained from an observational study of Holtzer et al.
nd resulted in total progressive disease costs for GClb of D 69,467. Research 50 (2016) 37–45
Becker et al. estimated total post-progression costs (according to
the label and treatment protocol) for GClb to be £3765 (D 5248).
5. Conclusions
Although this cost-effectiveness analysis has its limitations,
GClb currently appeared to be a cost-effective treatment strategy
compared to RClb, OClb and Clb. Results of this study can be used
to inform clinical guidelines and reimbursement decisions in The
Netherlands, and help to choose the optimal treatment. Neverthe-
less, a direct comparison should be made to supplement the current
evidence for GClb compared to OClb.
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